Volume 1.47 | Dec 7

Hematopoiesis News 1.47, December 7, 2010.  
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


New Clue in Leukemia Mystery: Researchers Identify “Poison” Employed by Deadly Enzyme Mutations  ShareThis
Investigators discovered that newly identified mutant enzymes in acute myelogenous leukemia create a chemical poison to cause leukemia. [Press release from the Weill Cornell Medical College discussing online prepublication in Cancer Cell]



Interested in recruiting talented individuals? Post your career opportunities in Hematopoiesis News at no cost. Contact us at [email protected]

Twitter Follow us on Twitter! @Hema_News


Tiny RNA Shown to Cause Multiple Types of Leukemia
Whitehead Institute researchers have shown in mouse models that overexpression of the microRNA 125b (miR-125b) can independently cause leukemia and accelerate the disease’s progression. [Press release from the Whitehead Institute for Biomedical Research discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

Study Identifies Potential Mechanism of Drug Resistance of CLL in Bone Marrow and Lymph Nodes
Investigators offer a new explanation of why chronic lymphocytic leukemia (CLL) tends to recur in the lymph nodes and bone marrow after being cleared from the bloodstream by chemotherapy. [Press release from the Dana-Farber Cancer Institute discussing data presented at the 52nd Annual Meeting of the American Society of Hematology (ASH)]

Phase I Trial Indicates Ponatinib May Thwart Most Resistant CML
A new drug appears to help chronic myeloid leukemia (CML) patients who are out of treatment options after first- and second-line drugs have failed them or because their cancer cells have a mutation that makes them resistant from the start, researchers reported. [Press release from the MD Anderson Cancer Center discussing data presented at the 52nd Annual Meeting of the American Society of Hematology (ASH)]

First Results from Phase II Study of Fractionated Radioimmunotherapy with Y-90 Epratuzumab in Aggressive Lymphoma Presented at Hematology Conference
Immunomedics, Inc., reported that consolidation treatment with fractionated yttrium-90 (Y-90) labeled epratuzumab, after induction therapy with rituximab and CHOP chemotherapy, improved remission status of adult patients with diffuse large B cell lymphoma, a form of aggressive lymphoma. [Press release from Immunomedics, Inc. discussing data presented at the 52nd Annual Meeting of the American Society of Hematology (ASH)]



Allogeneic Effector/Memory Th-1 Cells Impair FoxP3+ Regulatory T Lymphocytes and Synergize with Chaperone-Rich Cell Lysate Vaccine to Treat Leukemia
Here, researchers demonstrate that effector/memory CD4+ T helper-1 (Th-1) lymphocytes, in addition to polarizing type-1 anti-tumor immune responses, impair tumor-induced CD4+CD25+FoxP3+ regulatory T cell immunosuppressive function in vitro and in vivo. [Blood]

MicroRNA-125b Expands Hematopoietic Stem Cells and Enriches for the Lymphoid-Balanced and Lymphoid-Biased Subsets
Here, researchers show that microRNA-125b (miR-125b) is highly expressed in hematopoietic stem cells and its expression decreases in committed progenitors. [Proc Natl Acad Sci USA]

As4S4 Targets RING-Type E3 Ligase c-CBL to Induce Degradation of BCR-ABL in Chronic Myelogenous Leukemia
Arsenic, a curative agent for acute promyelocytic leukemia, induces cell apoptosis and degradation of BCR-ABL in chronic myelogenous leukemia (CML). Researchers demonstrated that ubiquitination and degradation of BCR-ABL was mediated by c-CBL, a RING-type E3 ligase that was also shown to be involved in ubiquitination for many other receptor/protein tyrosine kinases. [Proc Natl Acad Sci USA]

MicroRNA miR-125b Causes Leukemia
Researchers show that overexpression of miR-125b is sufficient both to shorten the latency of BCR-ABL-induced leukemia and to independently induce leukemia in a mouse model. [Proc Natl Acad Sci USA]

BCR/ABL Stimulates WRN to Promote Survival and Genomic Instability
In summary, researchers postulate that BCR/ABL-mediated stimulation of WRN modulates the efficiency and fidelity of major DNA double-strand break repair mechanisms to protect leukemia cells from apoptosis and to facilitate genomic instability. [Cancer Res]


Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
Cancer-associated IDH mutations are characterized by neomorphic enzyme activity and resultant 2-hydroxyglutarate production. Mutational and epigenetic profiling of a large acute myeloid leukemia (AML) patient cohort revealed that IDH1/2-mutant AMLs display global DNA hypermethylation and a specific hypermethylation signature. [Cancer Cell]

HLA-Matched Sibling Bone Marrow Transplantation for Beta-Thalassemia Major
Researchers describe outcomes after HLA-matched sibling bone marrow transplantation (BMT) for 179 patients with beta-thalassemia major. [Blood]

Rituximab-Cyclophosphamide-Dexamethasone Combination in the Management of Autoimmune Cytopenias Associated with Chronic Lymphocytic Leukemia
Researchers report their experience on rituximab-cyclophosphamide-dexamethasone (RCD) combination therapy for the treatment of autoimmune disorders (AIDs) in 48 chronic lymphocytic leukemia (CLL) patients. [Leukemia]

Inhibition of STAT5 by the Inhibitor of Janus Kinases Stimulates Dormant Human Leukemia CD34+/CD38- Cells and Sensitizes Them to Anti-Leukemia Agents
To verify molecular mechanisms by which leukemia stem cells (LSCs) maintain a dormant state, researchers explored the activity of the major pro-survival signal pathways in CD34+/CD38- compartment, supposed to contain LSCs, and CD34+/CD38+ counterparts from patients with acute myelogenous leukemia (AML, n=11) by fluorescence-activated cell sorting. [Int J Cancer]


Calistoga Pharmaceuticals Announces Positive Clinical Results from Ongoing Single-Agent and Combination Trials of CAL-101 in Patients with Hematologic Malignancies
Calistoga Pharmaceuticals, Inc. announced updated data from an ongoing single-agent trial and the first data from a combination trial of CAL-101, the company’s oral, delta-isoform-selective PI3K inhibitor. [Press release from Calistoga Pharmaceuticals, Inc. discussing data presented at the 52nd Annual Meeting of the American Society of Hematology (ASH)]

Robert Klein Reacts to Nomination to Second Term as Chair of CIRM Independent Citizens’ Oversight Committee
Robert N. Klein, author of Proposition 71 and Chairman of the Independent Citizens Oversight Committee, which oversees the California Institute for Regenerative Medicine (CIRM), reacted to his nomination by Governor Schwarzenegger and Lieutenant Governor Maldonado to a second term as Chair. [California Institute for Regenerative Medicine Press Release]

Arteriocyte Launches Stem Cell-Based Blood Research Product
Arteriocyte Inc. has launched a stem cell-based product that allows researchers to grow red blood cells outside the human body. [MedCity News]


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS (Listed by Date)

The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine
December 17-19, 2010
Guangzhou, China

Highlights of American Society of Hematology (ASH) Vancouver
January 21-22, 2011
Vancouver, Canada

Highlights of American Society of Hematology (ASH) Washington, D.C.
January 28-29, 2011
Washington, D.C., United States

Highlights of American Society of Hematology (ASH) San Francisco
January 28-29, 2011
San Francisco, United States

Highlights of American Society of Hematology (ASH) New York
February 4-5, 2011
New York, United States

Highlights of American Society of Hematology (ASH) San Diego
February 4-5, 2011
San Diego, United States

BMT Tandem Meetings (ASBMT/CIBMTR)
February 17-21, 2011
Honolulu, Hawaii

Molecular Medicine Tri-Conference: Inaugural Circulating Tumor Cells for Cancer Detection, Diagnosis, Prognosis and Treatment
February 23-25, 2011
San Francisco, United States

Cell Culture World Congress 2011 – Optimising Cell Culture Development for Biopharmaceutical, Bioprocessing and Manufacture
February 28-March 2, 2011
Munich, Germany

American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

PITTCON Conference & Expo 2011
March 13-18, 2011
Atlanta, United States

Keystone Symposia: Hematopoiesis
March 27-April 1, 2011
Big Sky, United States

United Kingdom National Stem Cell Network 2011 Annual Scientific Conference
March 30-April 1, 2011
York, United Kingdom

American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

37th Annual Meeting of the European Group for Blood and Marrow Transplantation
April 3-6, 2011
Paris, France

World Stem Cells & Regenerative Medicine Congress 2011
May 9-11, 2011
London, United Kingdom

International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies)

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost.

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us